Clinical Trial Update: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML [Phase 1, Phase 2]

View source ↗

Summary

A study of SLS009 (formerly GFH009), a potent CDK9 inhibitor, in hematologic malignancies including high-risk newly diagnosed acute myeloid leukemia, is in Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• SLS009 (GFH009)

Snippet

Sponsor: Sellas Life Sciences Group | Conditions: Hematologic Malignancies | Phase 1, Phase 2 | Status: RECRUITING